tbuckley/cabot-search huggingface dataset:
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Authors: Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, Hiroaki Ochiiwa, Yayoi Fujioka, Kimihiro Ito, Akihiro Miura, Takeshi Sagara, Satoru Ito, Hirokazu Ohsawa, Sachie Otsuki, Kaoru Funabashi, Masakazu Yashiro, Kenichi Matsuo, Kazuhiko Yonekura, Hiroshi Hirai
Journal: Cancer Research (2020)

FGFR signaling is deregulated in many human cancers, and FGFR is considered a valid target in FGFR-deregulated tumors. Here, we examine the preclinical profile of futibatinib (TAS-120; 1-[(3S)-[4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3, 4-d] pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one), a structurally novel, irreversible FGFR1-4 inhibitor. Among a panel of 296 human kinases, futibatinib selectively inhibited FGFR1-4 with IC50 values of 1.4 to 3.7 nmol/L. Futibatinib covalently bound the FGFR kinase domain, inhibiting FGFR phosphorylation and, in turn, downstream signaling in FGFR-deregulated tumor cell lines. Futibatinib exhibited potent, selective growth inhibition of several tumor cell lines (gastric, lung, multiple myeloma, bladder, endometrial, and breast) harboring various FGFR genomic aberrations. Oral administration of futibatinib led to significant dose-dependent tumor reduction in various FGFR-driven human tumor xenograft models, and tumor reduction was associated with sustained FGFR inhibition, which was proportional to the administered dose. The frequency of appearance of drug-resistant clones was lower with futibatinib than a reversible ATP-competitive FGFR inhibitor, and futibatinib inhibited several drug-resistant FGFR2 mutants, including the FGFR2 V565I/L gatekeeper mutants, with greater potency than any reversible FGFR inhibitors tested (IC50, 1.3-50.6 nmol/L). These results indicate that futibatinib is a novel orally available, potent, selective, and irreversible inhibitor of FGFR1-4 with a broad spectrum of antitumor activity in cell lines and xenograft models. These findings provide a strong rationale for testing futibatinib in patients with tumors oncogenically driven by FGFR genomic aberrations, with phase I to III trials ongoing. SIGNIFICANCE: Preclinical characterization of futibatinib, an irreversible FGFR1-4 inhibitor, demonstrates selective and potent antitumor activity against FGFR-deregulated cancer cell lines and xenograft models, supporting clinical evaluation in patients with FGFR-driven tumors. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/22/4986/F1.large.jpg.
993P NBTXR3 radiation enhancing hafnium oxide nanoparticles: RP2D for the treatment of HCC and liver metastases
Authors: T. de Baere, M. Pracht, Y. Rolland, J. Durand-Labrunie, N. Jaksic, F. Nguyen, J-P. Bronowicki, V. Vendrely, V. Croisé-Laurent, E. Rio, S. Le Sourd, P. Saïd, P. Gustin, C. Perret, D. Peiffert, E. Deutsch, E. Chajon
Journal: Annals of Oncology (2020)
1447P S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO
Authors: G.M. Haag, G. Stocker, S. Lorenzen, T.J. Ettrich, F. Longo, A. Kiani, M. Venerito, J. Trojan, R.J.C. Mahlberg, N. Moosmann, B. Chibaudel, S. Kubicka, R. Greil, S. Daum, M. Geissler, J. Mann, F. Lordick
Journal: Annals of Oncology (2020)
Human T Cells Expressing a CD19 CAR-T Receptor Provide Insights into Mechanisms of Human CD19-Positive β Cell Destruction
Authors: Haiting Ma, Jacob F. Jeppesen, Rudolf Jaenisch
Journal: Cell Reports Medicine (2020)

Autoimmune destruction of pancreatic β cells underlies type 1 diabetes (T1D). To understand T cell-mediated immune effects on human pancreatic β cells, we combine β cell-specific expression of a model antigen, CD19, and anti-CD19 chimeric antigen receptor T (CAR-T) cells. Coculturing CD19-expressing β-like cells and CD19 CAR-T cells results in T cell-mediated β-like cell death with release of activated T cell cytokines. Transcriptome analysis of β-like cells and human islets treated with conditioned medium of the immune reaction identifies upregulation of immune reaction genes and the pyroptosis mediator GSDMD as well as its activator CASP4. Caspase-4-mediated cleaved GSDMD is detected in β-like cells under inflammation and endoplasmic reticulum (ER) stress conditions. Among immune-regulatory genes, PDL1 is one of the most upregulated, and PDL1 overexpression partially protects human β-like cells transplanted into mice. This experimental platform identifies potential mechanisms of β cell destruction and may allow testing of therapeutic strategies.
Are T cells helpful for COVID-19: the relationship between response and risk
Authors: Diane E. Griffin
Journal: Journal of Clinical Investigation (2020)

The disease spectrum of coronavirus disease 2019 (COVID-19) ranges from no symptoms to multisystem failure and death. Characterization of virus-specific immune responses to severe acute respiratory coronavirus 2 (SARS-CoV-2) is key to understanding disease pathogenesis, but few studies have evaluated T cell immunity. In this issue of the JCI, Sattler and Angermair et al. sampled blood from subjects with COVID-19 and analyzed the activation and function of virus antigen-specific CD4+ T cells. T cells that failed to respond to peptides from the membrane, spike, or nucleocapsid proteins were more common in subjects who died. In those whose T cells had the capacity to respond, older patients with comorbidity had larger numbers of activated T cells compared with patients who had fewer risk factors, but these cells showed impaired IFN-γ production. This cross-sectional study relates activated T cell responses to patient risk factors and outcome. However, T cell response trajectory over the disease course remains an open question.
670P LINAC-based re-irradiation for locally recurrent prostate cancer after first course radiotherapy
Authors: F. Cuccia, L. Nicosia, R. Mazzola, V. Figlia, N. Giaj-Levra, F. Ricchetti, M. Rigo, C. Vitale, S. Corradini, R. Ruggieri, F. Alongi
Journal: Annals of Oncology (2020)
180P Development of prognosis prediction model using cytokeratin 19 mRNA copy number of sentinel lymph node metastasis in breast cancer: A multicenter study in Japan
Authors: D. Yotsumoto, T. Osako, M. Matsuura, S. Takayama, K. Kaneko, M. Takahashi, K. Shimazu, K. Yoshidome, K. Kuraoka, M. Itakura, M. Tani, T. Ishikawa, Y. Ohi, T. Kinoshita, N. Sato, M. Tsujimoto, H. Tsuda, S. Nakamura, S. Noguchi, F. Akiyama
Journal: Annals of Oncology (2020)
Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
Authors: Deborah P. Merke, Richard J. Auchus
Journal: New England Journal of Medicine (2020)

Congenital adrenal hyperplasia, a common autosomal recessive disorder, is potentially life-threatening in its classic form and may be asymptomatic or cause female infertility in its nonclassic form. This review focuses on CAH due to 21-hydroxylase deficiency.
273O nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
Authors: E.P. Hamilton, J. Cortés, O. Ozyilkan, S-C. Chen, K. Petrakova, A. Manikhas, G. Jerusalem, R. Hegg, J. Huober, S.C. Chapman, Z. Yang, Y. Chen, E.L. Johnston, M. Martin
Journal: Annals of Oncology (2020)
777P Decrease in derived neutrophil-to-lymphocyte ratio (dNLR) related to immune checkpoint inhibitors (ICI) benefit in patients with metastatic urothelial carcinoma (mUC)
Authors: H.K. Oberoi, L. Ghiglione, T. Gorría Puga, L. Fernández Mañas, L. Ferrer Mileo, M. Orrillo Sarmiento, A. Prat, O. Reig Torras, B. Mellado
Journal: Annals of Oncology (2020)
1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE score
Authors: E. Seguí, E. Auclin, D. Casadevall, J. Aguilar-Company, M. Rodriguez, N. Epaillard, M. Tagliamento, S. Pilotto, R. López-Castro, X. Mielgo, C. Urbano, A. Rodríguez, D. García-Illescas, M.V. Bluthgen, L. Masfarré, H. Oliveres, J.N. Minatta, J. Marco-Hernández, A. Prat, L. Mezquita
Journal: Annals of Oncology (2020)
351TiP SOLTI-1507: A phase Ib study of ipatasertib and anti-HER2 therapy in HER2-positive advanced breast cancer with PIK3CA mutation (IPATHER)
Authors: M. Oliveira, P. Villagrasa, E.M. Ciruelos, J. Gavilá, A. Cortegoso, F. Henao, E. Vega, J. Salvador, V. Quiroga, L.G. Estevez, S. Morales, P. Tolosa, F. Salvador, X. Gonzalez, C. Saura
Journal: Annals of Oncology (2020)
1691P Evaluation of practice variation for cancer patients care in a French cancer center during the COVID-19 outbreak
Authors: D. Borchiellini, J-M. Hannoun-Levi, J. Gal, M. Gosset, E. Besrest, E. Francois, A. Pilato, J-M. Ferrero, E. Barranger
Journal: Annals of Oncology (2020)
192P The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada
Authors: P. Blanchette, M. Lam, B. Le, L. Richard, S. Shariff, K. Pritchard, J. Raphael, T.A. Vandenberg, R. Fernandes, D. Desautels, K. Chan, C. Earle
Journal: Annals of Oncology (2020)
Granulomatous Amebic Encephalitis
Authors: Matt Schimmel, Ishan Mehta
Journal: New England Journal of Medicine (2020)

An 82-year-old man presented with generalized weakness. He had rapidly progressive neurologic symptoms and died 9 days later. Autopsy showed liquefactive necrosis of the brain, and a diagnosis of granulomatous amebic encephalitis was made.
1182P Baseline neutrophil-lymphocyte ratio and its variations after adjuvant radiotherapy predict clinical survival outcomes in locally advanced Merkel cell carcinoma (MCC)
Authors: M. Torchio, F. Corti, P. Manca, N. Prinzi, M. Platania, A. Maurichi, I. Mattavelli, R. Patuzzo, N. Bedini, M. Milione, L. Cattaneo, T. Beninato, M. Prisciandaro, A. Raimondi, F. Pagani, E. Colombo, J. Coppa, M. Di Bartolomeo, F.G. de Braud, S. Pusceddu
Journal: Annals of Oncology (2020)
The 2020 Lasker Awards and the COVID-19 Pandemic
Authors: Joseph L. Goldstein
Journal: JAMA (2020)

The 2020 Lasker Awards will not be given this year owing to the global coronavirus disease 2019 (COVID-19) pandemic.One way to help fill this void is to reflect and celebrate the major advances in infectious disease research that have been honored with Lasker Awards over the last 75 years.Since 1946, when the Lasker Awards were first presented, 29 awards have been bestowed on 5 organizations and 35 individuals who expanded scientific knowledge concerning how viruses and other infectious pathogens cause disease (7 awards), how infections can be treated with drugs (7 awards), and how infections can be prevented with vaccines (15 awards).
初期のCD7陽性T細胞急性リンパ性白血病におけるT細胞受容体Dデルタ2(Dデルタ)Jデルタ再編成の高い有病率
Authors: Kimura N, Akiyoshi T, Uchida T, Okamura J, Kozuru M, Nishimura J, Ohyashiki Jh, Kikuchi M, Niho Y, Okumura M
Journal: Leukemia (1996)
595P Abdominal events in targeted therapies: Report from the Drug Rediscovery Protocol (DRUP)
Authors: L.J. Zeverijn, L.R. Hoes, H. van der Wijngaart, J.M. van Berge Henegouwen, H. Gelderblom, H.M.W. Verheul, E.E. Voest
Journal: Annals of Oncology (2020)
Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016
Authors: Anne T. Knisely, Caryn M. St. Clair, June Y. Hou, Fady Khoury Collado, Dawn L. Hershman, Jason D. Wright, Alexander Melamed
Journal: JAMA Network Open (2020)

Three published clinical trials1-3 that randomized women with advanced-stage ovarian cancer to primary cytoreductive surgery before adjuvant chemotherapy or neoadjuvant chemotherapy before interval cytoreductive surgery found no evidence of a progression-free or overall survival advantage for either approach. However, those studies did demonstrate a reduction in surgical morbidity in women assigned to neoadjuvant chemotherapy. Nonetheless, most gynecologic oncologists believe that primary surgical treatment is the preferred approach for advanced ovarian cancer.4 Since the publication of the first of those 3 randomized trials in 2010,1 the use of neoadjuvant chemotherapy for ovarian cancer has increased in the US.5 The objective of this study was to examine and compare time trends in the use of neoadjuvant chemotherapy and the median survival among women with advanced-stage epithelial ovarian cancer in the United States.
LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Authors: K.N. Moore, M. Bookman, J. Sehouli, A. Miller, C. Anderson, G. Scambia, T. Myers, C. Taskiran, K. Robison, J. Maenpaa, L.J. Willmott, N. Colombo, J. Thomes-Pepin, M.A. Gold, C. Aghajanian, F. Wu, L. Molinero, V. Khor, Y.G. Lin, S. Pignata
Journal: Annals of Oncology (2020)
Correction to: Lung ultrasound predicts clinical course and outcomes in COVID-19 patients
Authors: Yael Lichter, Yan Topilsky, Philippe Taieb, Ariel Banai, Aviram Hochstadt, Ilan Merdler, Amir Gal Oz, Jacob Vine, Or Goren, Barak Cohen, Orly Sapir, Yoav Granot, Tomer Mann, Shirley Friedman, Yoel Angel, Nimrod Adi, Michal Laufer-Perl, Merav Ingbir, Yaron Arbel, Idit Matot, Yishay Szekely
Journal: Intensive Care Medicine (2020)

The original article can be found online.
1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma
Authors: M. Reni, F. Bergamo, E. Giommoni, M. Milella, L. Cavanna, M.C. Di Marco, F. Artioli, N. Silvestris, M. Spada, M. Ghidini, E. Maiello, G.G. Cardellino, M. Macchini, G. Orsi, C. Manai, M.M. Valente, V. Torri, L. Porcu, V. Giugliano, G.D. Beretta
Journal: Annals of Oncology (2020)
981O Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial
Authors: M. Shi, Q. Li, M. He, R. Guo
Journal: Annals of Oncology (2020)
191P Therapeutic drug monitoring of tamoxifen to improve adjuvant treatment of hormone sensitive breast cancer: The TOTAM study
Authors: L. Braal, A. Jager, K.M. Lommen, E. Oomen-de Hoop, P. de Bruijn, M.B. Vastbinder, Q.C. van Rossum-Schornagel, M.F. Thijs-Visser, R. van Alphen, E.M. Struik, J.M. Zuetenhorst, R.H. Mathijssen, S.L. Koolen
Journal: Annals of Oncology (2020)
902P Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting
Authors: T. Ionova, L. Anchukova, S. Dubov, T. Esenina, L. Ivanova, K. Kaplanov, Y. Kochkareva, A. Kopylova, T. Kravchuk, A. Levanov, O. Li, T.P. Nikitina, O. Rukavitsyn, N. Saraeva, M. Savinova, T. Shelekhova, P. Simashova, M. Shirokova, O. Vinogradova, S. Volkova
Journal: Annals of Oncology (2020)
934P Comparing frailty screening tools for older head and neck cancer patients
Authors: M. Antonio, M. Honorato, M. Plana, A. Lozano, S. Llop, V. Gomez, E. Vilajosana, M. Oliva, C. Arranz, R. Mesía, J. Nogués, M. Taberna Sanz
Journal: Annals of Oncology (2020)
Outcomes of Cardiopulmonary Resuscitation in Patients With COVID-19—Limited Data, but Further Reason for Action
Authors: Matthew E. Modes, Robert Y. Lee, J. Randall Curtis
Journal: JAMA Internal Medicine (2020)

Outcomes of Cardiopulmonary Resuscitation in Patients With COVID-19-Limited Data, but Further Reason for ActionCardiopulmonary resuscitation (CPR) for in-hospital cardiac arrest (IHCA) in patients with coronavirus disease 2019 (COVID-19) presents unique challenges.Cardiopulmonary resuscitation may be delayed because of isolation procedures, and advanced life support resources may be limited.Additionally, CPR for patients with COVID-19 exposes health care workers to increased risk of viral transmission.Improving our understanding of the likelihood of successful outcomes after CPR is crucial to informing goals-of-care discussions, determining the appropriateness of resuscitative efforts, and guiding policy.To date, to our knowledge, there is limited evidence on outcomes for IHCA among patients with COVID-19.A single-center study of 136 patients with IHCA in Wuhan, China, reported poor outcomes but was limited by cardiac arrests occurring during shortages of advanced life support resources. 1 Nonetheless, this study found only 18 patients (13%) achieved return of spontaneous circulation, 4 (3%) survived to 30 days, and only 1 (<1%) achieved a favorable neurological outcome by 30 days.In this issue of JAMA Internal Medicine, Thapa et al 2 report what to our knowledge are the first US data on outcomes for IHCA among patients with COVID-19.In their case series of 54 patients, 52 (96%) had a nonshockable initial rhythm, 29 (54%) achieved return of spontaneous circulation, and 0 survived to hospital discharge (95% CI, 0%-6.6%).This very low hospital survival is likely driven by several factors, including critical illness in most patients at the time of arrest and the many patients with nonshockable initial rhythms.Additionally, presumed respiratory etiology of arrest for most patients, lack of therapies to effectively treat the underlying disease, and potential delays in response time for donning of personal protective equipment may have contributed to poor outcomes.These small case series reporting hospital survival after IHCA among patients with COVID-19 must be interpreted with caution, as only 1 or 2 additional survivors would make important differences in the observed estimates.Outcomes in the setting of COVID-19 may not actually differ from pre-COVID-19 outcomes of IHCA for patients with nonshockable rhythms, for whom hospital survival is often less than 15%. 3 Nonetheless, this article 2 represents important early evidence suggesting outcomes for IHCA in patients with COVID-19 pneumonia are likely poor, particularly among patients with respiratory failure.Improving outcomes for patients with severe illness with COVID-19 and IHCA will be
A snake toxin as a theranostic agent for the type 2 vasopressin receptor
Authors: Laura Droctové, Manon Lancien, Vu Long Tran, Michaël Susset, Benoit Jego, Frederic Theodoro, Pascal Kessler, Gilles Mourier, Philippe Robin, Sékou Siramakan Diarra, Stefano Palea, Adrien Flahault, Amélia Chorfa, Maithé Corbani, Catherine Llorens-Cortes, Bernard Mouillac, Christiane Mendre, Alain Pruvost, Denis Servent, Charles Truillet, Nicolas Gilles
Journal: Theranostics (2020)

de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
1191P CUN-BAE vs BMI as a breast cancer risk predictor
Authors: I. Delgado Sillero, N. Lopetegui Lia, N. Cubelos, L.F. Sánchez-Cousido, M. Rojas Piedra, B. Tavara Silva, M.L. Garrido Onecha, V. Martín
Journal: Annals of Oncology (2020)
No association between IL28B genotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepatitis B in three large randomized clinical studies
Authors: Lai Wei, Heiner Wedemeyer, Yun-Fan Liaw, Henry Lik-Yuen Chan, Teerha Piratvisuth, Patrick Marcellin, Jidong Jia, Deming Tan, Wan-Cheng Chow, Maurizia R Brunetto, Moises Diago, Selim Gurel, Viacheslav Morozov, Hua He, Yonghong Zhu, Cynthia Wat, Alexander J Thompson
Journal: Hepatology (2013)
LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis of second progression-free survival (PFS2) in the phase III PAOLA-1/ENGOT-ov25 trial
Authors: A. González Martín, Y. Tazi, F. Heitz, L. Montane, P. Gargiulo, R. Berger, K. Yonemori, I. Vergote, A. Bologna, J. Maenpaa, C. Costan, U. Canzler, C. Zamagni, E.M. Guerra-Alia, C.B. Levaché, F. Marmé, E. Kalbacher, N. De Gregorio, N. Dohollou, I.L. Ray-Coquard
Journal: Annals of Oncology (2020)
1551P Validation of response and survival biomarkers in a phase II trial of BPM 31510-IV in advanced refractory pancreatic ductal adenocarcinoma (PDAC)
Authors: V. Subbiah, M.D. Nastke, G.M. Miller, P. Shah, S. Gesta, L.O. Rodrigues, E. Granger, N.R. Narain, M.A. Kiebish, R. Sarangarajan, M.N. Kundranda
Journal: Annals of Oncology (2020)
797TiP RACE IT: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative radiation therapy before radical cystectomy combined with immunotherapy in locally advanced urothelial carcinoma of the bladder (AB 65/18)
Authors: S.C. Schmid, F. Beckert, F. Koll, C. Rödel, A.K. Seitz, P. Maisch, A. Sauter, H. Kübler, M. Flentje, S.E. Combs, K. Schiller, J. Gschwend, M. Retz
Journal: Annals of Oncology (2020)
LBA83 Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: A multi-centre North London experience
Authors: N. Nalinie Joharatnam-Hogan, D. Daniel Hochhauser, K-K. Shiu, H. Rush, V. Crolley, E. Butcher, A. Sharma, A. Muhammad, N. Vasdev, M. Anwar, G. Kantser, A. Saha, F. Raja, J. Bridgewater, K.H. Khan
Journal: Annals of Oncology (2020)
1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts)
Authors: R. Ferrara, F. Facchinetti, G. Calareso, I. Kasraoui, D. Signorelli, C. Proto, A. Prelaj, C. Naltet, P. Lavaud, R. Desmaris, G. Viscardi, G. Galli, A. De Toma, A. Martinetti, F. Barlesi, D. Planchard, J-C. Soria, M.C. Garassino, B. Besse, G. Lo Russo
Journal: Annals of Oncology (2020)
Hemoglobin-mediated biomimetic synthesis of paramagnetic O<sub>2</sub>-evolving theranostic nanoprobes for MR imaging-guided enhanced photodynamic therapy of tumor
Authors: Xiudong Shi, Weitao Yang, Qiong Ma, Yang Lu, Yan Xu, Kexin Bian, Fengjun Liu, Chunzi Shi, Han Wang, Yuxin Shi, Bingbo Zhang
Journal: Theranostics (2020)

The hypoxic microenvironment in solid tumors severely limits the efficacy of photodynamic therapy (PDT). Therefore, the development of nanocarriers co-loaded with photosensitizers and oxygen, together with imaging guidance ability, is of great significance in cancer therapy. However, previously reported synthetic methods for these multi-functional probes are complicated, and the raw materials used are toxic. Methods: Herein, the human endogenous protein, hemoglobin (Hb), was used for the simultaneous biomimetic synthesis of Gd-based nanostructures and co-loading of Chlorine e6 (Ce6) and oxygen for alleviating the hypoxic environment of tumors and accomplishing magnetic resonance imaging (MRI)-guided enhanced PDT. The Gd@HbCe6-PEG nanoprobes were synthesized via a green and protein biomimetic approach. The physicochemical properties, including relaxivity, oxygen-carrying/release capability, and PDT efficacy of Gd@HbCe6-PEG, were measured in vitro and in vivo on tumor-bearing mice after intravenous injection. Morphologic and functional MRI were carried out to evaluate the efficacy of PDT. Results: The results demonstrated the successful synthesis of compact Gd@HbCe6-PEG nanostructures with desired multi-functionalities. Following treatment with the nanoparticles, the embedded MR moiety was effective in lighting tumor lesions and guiding therapy. The oxygen-carrying capability of Hb after biomimetic synthesis was confirmed by spectroscopic analysis and oxygen detector in vitro. Further, tumor oxygenation for alleviating tumor hypoxia in vivo after intravenous injection of Gd@HbCe6-PEG was verified by photoacoustic imaging and immunofluorescence staining. The potent treatment efficacy of PDT on early-stage was observed by the morphologic and functional MR imaging. Importantly, rapid renal clearance of the particles was observed after treatment. Conclusion: In this study, by using a human endogenous protein, we demonstrated the biomimetic synthesis of multi-functional nanoprobes for simultaneous tumor oxygenation and imaging-guided enhanced PDT. The therapeutic efficacy could be quantitatively confirmed at 6 h post PDT with diffusion-weighted imaging (DWI).